Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition and application of medicine composition to preparing medicines for preventing and treating atherosclerosis and dyslipidemia

A technology of dyslipidemia and composition, applied in the field of medicine, can solve the problems of no obvious advantage in long-term curative effect, unsatisfactory curative effect, side effects, etc., achieve improvement of aortic lesion, good synergistic anti-atherosclerosis, and increase activity Effect

Active Publication Date: 2015-10-21
TAISHAN MEDICAL UNIV
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, the main treatment for atherosclerosis is the use of angiogenesis inhibitors and lipid-lowering drugs, but the curative effect is not ideal, and often accompanied by side effects
Although interventional therapy can recanalize blood vessels, restenosis is a medical problem that cannot be solved at present, especially the long-term efficacy has no obvious advantages

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition and application of medicine composition to preparing medicines for preventing and treating atherosclerosis and dyslipidemia
  • Medicine composition and application of medicine composition to preparing medicines for preventing and treating atherosclerosis and dyslipidemia
  • Medicine composition and application of medicine composition to preparing medicines for preventing and treating atherosclerosis and dyslipidemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Therapeutic effects of quercetin and N-acetylneuraminic acid on atherosclerosis model mice

[0021] SPF grade apolipoprotein E knockout (apoE- / -) mice, male, weighing 20±2 g. Under the experimental conditions, the normal feed was given adaptive feeding for 1 week, and the experimental animals were randomly divided into 5 groups: 12 animals in the blank group, 15 animals in the model group, 15 animals in the quercetin group, 15 animals in the N-acetylneuraminic acid group and the combination group. A group of 15. Except for the blank group, all rats were given high-fat feed (formula: cholesterol 1.25%, bile salt 0.5%, lard 10%, egg yolk powder 10%, basal feed 78.25%); the blank group was given normal feed. After feeding for 1 month, each group was given the corresponding drug by gavage at 0.2 mL / kg under the condition of unchanged feed, and the blank group and model group were given the same volume of normal saline, once a day, for 2 consecutive months. The test drugs ...

Embodiment 2

[0030] Treatment of rutin and N-acetylneuraminic acid on atherosclerosis model mice

[0031] SPF grade apolipoprotein E knockout (apoE- / -) mice, male, weighing 20±2 g. Under the experimental conditions, the normal feed was given adaptive feeding for 1 week, and the experimental animals were randomly divided into 5 groups: 12 animals in the blank group, 12 animals in the model group, 12 animals in the rutin group, 12 animals in the N-acetylneuraminic acid group and combination B Group of 12. Except for the blank group, all rats were given high-fat feed (formula: cholesterol 1.25%, bile salt 0.5%, lard 10%, egg yolk powder 10%, basal feed 78.25%); the blank group was given normal feed. After feeding for 1 month, each group was given the corresponding drug by gavage at 0.2 mL / kg under the condition of unchanged feed, and the blank group and model group were given the same volume of normal saline, once a day, for 2 consecutive months. The test drugs and doses of each group are a...

Embodiment 3

[0041] Treatment of atherosclerosis model mice with the combination of quercetin and rutin combined with N-acetylneuraminic acid

[0042] SPF grade apolipoprotein E knockout (apoE- / -) mice, male, weighing 20±2 g. Under the experimental conditions, the animals were given adaptive feeding with ordinary feed for 1 week, and the experimental animals were randomly divided into 5 groups: 12 animals in the blank group, 12 animals in the model group, 12 animals in the mixed quercetin rutin group, and 12 animals in the N-acetylneuraminic acid group. Only and combination C group 12. Except for the blank group, all rats were given high-fat feed (formula: cholesterol 1.25%, bile salt 0.5%, lard 10%, egg yolk powder 10%, basal feed 78.25%); the blank group was given normal feed. After feeding for 1 month, each group was given the corresponding drug by gavage at 0.2 mL / kg under the condition of unchanged feed, and the blank group and model group were given the same volume of normal saline,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine composition and application of the medicine composition to preparing medicines for preventing and treating atherosclerosis, dyslipidemia and related diseases. Flavonoids compounds and sialic acid N-acetylneuraminic acid are combined to be applied to an atherosclerotic model apoprotein-carried knockout mouse. Through the experimental study, it is found that the medicine composition can obviously adjust lipid metabolism, reduce the content of triglyceride, cholesterol, malonaldehyde and oxidized low-density lipoprotein in plasmas, improve the activity of superoxide dismutase and lipoprotein esterase of the high-fat-induced arterial model mouse (apoprotein-carried knockout mouse), reduce lipid deposition of the lipid in the liver and the arcus aortae of the apoprotein-carried knockout mouse, relieve the aortic disease conditions, and obtain the unexpected curative effect of the cooperativity atherosclerosis.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition and its application in the preparation of medicines for preventing and treating atherosclerosis and dyslipidemia. Background technique [0002] Cerebrovascular disease is a disease with high morbidity, high disability rate, and high fatality rate. or bleeding disorders. There are many causes, one of which is atherosclerosis. Atherosclerosis can lead to narrowing of arterial lumen, insufficient blood supply to brain tissue, and even serious consequences due to plaque shedding and blockage of cerebral blood vessels. [0003] The main lesion feature of atherosclerosis is the subintimal lipid deposition in some parts of the artery, accompanied by the proliferation of smooth muscle cells and fiber components, and gradually develops to form local plaques, which thicken and harden the arterial wall. The necrosis and disintegration of the block...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7028A61K31/7048A61P9/10A61P3/06A61K31/352
Inventor 郭守东田华秦树存张颖
Owner TAISHAN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com